Tiotropium and chronic obstructive pulmonary disease

BMJ (Online)

Volumn 340, Issue 7746, 2010, Pages 546-

  McIvor, R Andrew ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; SALMETEROL; TIOTROPIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; DYSPNEA; EDITORIAL; EXERCISE TOLERANCE; HUMAN; HYPERINFLATION; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER;

CARDIOVASCULAR DISEASES; CHOLINERGIC ANTAGONISTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 77949415673     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c833     Document Type: Editorial

References (12)

1. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62. [Abstract/Free Full Text]
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. 2009. www.goldcopd.com/ Guidelineitem.asp?l1=2&l2=1&intId=2003.
3. Griffin J, Lees, Caiado M, Kesten S, Price D. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK general practice research database 12-month follow-up study. Prim Care Respir J 2008;17:104-10. [CrossRef][Medline]
4. Van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat soft mist inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9.[CrossRef][Web of Science][Medline]
5. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90. [Abstract/Free Full Text]
6. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50. [Abstract/Free Full Text]
7. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54. [Abstract/Free Full Text]
8. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30. [Abstract/Free Full Text]
9. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. [Abstract/Free Full Text]
10. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. [Abstract/Free Full Text]
11. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009;374:721-32.[CrossRef] [Web of Science][Medline]
12. Caverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 Study Groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94. [CrossRef][Web of Science][Medline]